Gentag is a visionary IP and technology development company that combines its advanced knowledge in biology, chemistry, microelectronics, and artificial intelligence to convert consumer safety and health concerns into everyday disposable sensors that will revolutionize diagnostics, proactive medicine, nutrition and the everyday lives of consumers worldwide.
Gentag, Inc. and its patent holding company, Altivera, LLC, hold 66 issued patents covering cell phone-based consumer safety sensors, IoT sensors and sensors for instant diagnostic tests. These combined technologies allow for a range of groundbreaking consumer applications, from simple IoT sensor readings such as temperature or packaging tamper resistance, to sophisticated consumer health applications including biomarker analyses and COVID-19 detection.
In addition to its wireless sensor portfolio, Gentag is also developing an optical blockchain sensor platform for new types of consumer market sensing applications. Optical blockchain sensors have broad market applications, including for food safety, bacterial detection, consumer health and mobile payments. They can be mass produced rapidly and at a very low cost.
John Peeters, Ph.D., Founder and CEO
Dr. John Peeters is an expert on biomarkers, sensors, and nanotechnologies. He holds numerous issued U.S. and international patents. John obtained a doctorate in applied biology from Cambridge University in the UK. He also holds a master’s degree in genetics and a bachelor’s honors degree in biology. Dr. Peeters predicted and patented a number of key technologies well before their time, including radar responsive sensor tags (US patent 6031454), DNA sequencing in a nanotube (US patent 6123819), NFC cell phones sensor networks (US patent 7148803), and the closed loop cell phone insulin delivery system or “artificial pancreas” (US patent 8077042).
Alfred R. Berkeley, III serves as the Vice Chairman of Gentag. Previously, he served as the President of NASDAQ. He has served as Chairman of the President’s National Infrastructure Advisory Council, as a Trustee of Johns Hopkins University, and as a Governor of the National Association of Securities Dealers. Mr. Berkeley is also a former Director of the World Economic Forum USA. He received his M.B.A. from the Wharton School.
Rita Colwell, Ph.D.
Rita Colwell is Distinguished University Professor at the University of Maryland, College Park and the Johns Hopkins University Bloomberg School of Public Health. She was the 11th Director of the National Science Foundation, and is a recipient of the 2006 US National Medal of Science. Dr. Colwell is a member of the US National Academy of Sciences, has authored or co-authored 16 books, has published over 800 scientific papers, and has received 61 honorary degrees. She serves as Chief Science Officer of Gentag.
Larry Bottomley, Ph.D.
Lawrence Bottomley is Professor Emeritus of Chemistry at the Georgia Institute of Technology. He is an analytical chemist with expertise in nanotechnology, surface characterization, electrochemistry, and interfacial engineering; holds two patents; and has published over 150 scientific papers. Professor Bottomley works with Gentag in sensor design and electrochemistry.
Daniel Layish, M.D.
Dr. Daniel Layish is a pulmonologist based in Orlando, Florida specialized in treating cystic fibrosis. He received his medical degree from Boston University School of Medicine, serves as an Associate Professor at the University of Central Florida School of Medicine, and has been in practice for over 25 years. Dr. Layish serves as Medical Director of Gentag.
Mike Lovejoy, Ph.D.
Dr. Mike Lovejoy developed the Radar Responsive tag while at Sandia National Laboratories and is an expert in wireless chip technologies, ASIC designs, and geolocation. Previously, he worked at the Xilinx Corporation and Philips Semiconductors as a senior chip designer. He is the co-inventor of US Patent 6031454, jointly with Dr. Peeters. Mike obtained a doctorate in electrical engineering from Purdue University.
Joshua Silver, Ph.D.
Professor Joshua Silver is an atomic physicist and vision scientist from the University of Oxford. He was the first person to recognize that self-refraction opens the way to the delivery of high optical quality but very inexpensive eyewear to large underserved populations in the developing world, work which led the European Patent Office to nominate him as Inventor of the Year in 2011. In the current Covid-19 pandemic, he has turned his attention to the development and mass manufacture of an inexpensive optical virus detector. He serves as Head of Optics of Gentag.
David Hoel, Ph.D.
David Hoel is a Distinguished University Professor in the School of Medicine at the Medical University of South Carolina. He was trained in mathematics and statistics at the University of California (Berkeley) with highest honors and received his Ph.D. from the University of North Carolina (Chapel Hill) followed by a Public Health Services’ post-doctoral fellowship in preventive medicine at Stanford University. Professor Hoel is a leading biostatistician and an expert in the area of chemical and radiation health effects and quantitative risk assessment with 200 scientific publications. He served as Director of the Division of Biometry and Risk Assessment at the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health. He is a member of the National Academy of Medicine, as well as a National Associate of the National Academy of Sciences and the National Research Council. Professor Hoel works with Gentag in the area of biomarker discovery and pre-disease detection using Artificial Intelligence (AI).